WO2004041807A1 - Nouveaux composes - Google Patents

Nouveaux composes Download PDF

Info

Publication number
WO2004041807A1
WO2004041807A1 PCT/EP2003/012406 EP0312406W WO2004041807A1 WO 2004041807 A1 WO2004041807 A1 WO 2004041807A1 EP 0312406 W EP0312406 W EP 0312406W WO 2004041807 A1 WO2004041807 A1 WO 2004041807A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
compounds
optionally substituted
pharmaceutically acceptable
Prior art date
Application number
PCT/EP2003/012406
Other languages
English (en)
Inventor
Steven Coulton
Roderick Alan Porter
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to AU2003279366A priority Critical patent/AU2003279366A1/en
Publication of WO2004041807A1 publication Critical patent/WO2004041807A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to N-aryl sulphonyl cyclic amine derivatives and their use as pharmaceuticals. Many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second messengers.
  • Polypeptides and polynucleotides encoding the human 7-transmembrane G-protein coupled neuropeptide receptor, orexin-1 have been identified and are disclosed in EP-A-875565, EP-A-875566 and WO 96/34877.
  • Polypeptides and polynucleotides encoding a second human orexin receptor, orexin-2 have been identified and are disclosed in EP-A-893498.
  • Orexin receptors are found in the mammalian host and may be responsible for many biological functions, including pathologies including, but not limited to, depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis/disorder; depressive neurosis/disorder; anxiety neurosis; dysthymic disorder; behaviour disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; sex disorder; sexual disorder; schizophrenia; manic depression; delerium; dementia; severe mental retardation and dyskinesias such as Huntington's disease and Gilles de la Tourett's syndrome; disturbed biological and circadian rhythms; feeding disorders, such as anorexia, bulimia, cachexia, and obesity; diabetes; appetite/taste disorders; vomiting/nausea; asthma; cancer
  • HIV, post-polio syndrome, and post-herpetic neuralgia phantom limb pain; labour pain; cancer pain; post-chemotherapy pain; post-stroke pain; post- operative pain; neuralgia; nausea and vomiting; conditions associated with visceral pain including irritable bowel syndrome, migraine and angina; urinary bladder incontinence e.g.
  • narcotics or withdrawal from narcotics sleep disorders; sleep apnea; narcolepsy; insomnia; parasomnia; jet-lag syndrome; and neurodegenerative disorders, which includes nosological entities such as disinhibition-dementia-parkinsonism- amyotrophy complex; pallido-ponto-nigral degeneration, epilepsy, and seizure disorders.
  • antagonists of its receptor may be useful in the treatment of obesity and diabetes, see Cell, 1998, 92, 573-585.
  • the present invention provides N-aryl sulphonyl cyclic amine derivatives which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors.
  • these compounds are of potential use in the treatment of obesity, including obesity observed in Type 2 (non-insulin-dependent) diabetes patients, and/or sleep disorders. Additionally these compounds are useful in the treatment of stroke, particularly ischemic or haemorrhagic stroke, and/or blocking the emetic response, i.e. useful in the treatment of nausea and vomiting.
  • X is NR, wherein R is H or (C 1-4 )alkyl; Q is H or (C 1-4 )alkyl;
  • Ar 1 is aryl, or a mono or bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; any of which maybe optionally substituted;
  • Ar 2 represents phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heterocyclyl group is substituted by R 1 and further optional substituents; or Ar 2 represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 4 heteroatoms selected from N, O and S;
  • R 1 represents hydrogen, optionally substituted(C 1- )alkoxy, halo, cyano, optionally substituted(C 1-6 )alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6- membered heterocyclic ring containing up to 4 heteroatoms selected from N, O and S; or a pharmaceutically acceptable salt thereof.
  • m is 1 when p is 0.
  • X is NH; m is 1 and p is 0.
  • Ar 1 is a mono or bicyclic heteroaryl
  • Ar 1 is benzofuranyl, quinoxalinyl, pyridinyl or pyrimidinyl.
  • Ar 2 is a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S, it may be furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazinyl, pyrimidinyl, isothiazolyl, isoxazolyl, pyrazinyl or pyrazolyl.
  • Ar 2 is an optionally substituted bicyclic aromatic or bicyclic heteroaromatic it is selected from benzofuryl, benzimidazolyl, quinolinyl, quinoxalinyl, naphthyl, benzotriazolyl, benzothienyl, benzoxazolyl, naphthyridinyl, isoqumolinyl, quinazolinyl, indolyl, benzothiazolyl, or benzothiadiazolyl.
  • Ar 2 represents optionally substituted phenyl, pyridyl, thiazolyl, pyrazolyl, benzofuryl, naphthyl, triazolyl, quinoxalinyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothienyl, benzotriazolyl, benzothiazolyl, indolyl or thienyl.
  • Ar 2 represents optionally substituted phenyl or napthyl.
  • R 1 is a 5- or 6-membered heterocyclyl group containing up to 4 heteroatoms selected from N, O and S, it maybe furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazinyl, pyrimidinyl, isothiazolyl, isoxazolyl, pyrazinyl, pyrazolyl, tetrazoyl, piperazinyl, piperidinyl, mo ⁇ holinyl or thiomo ⁇ holinyl.
  • R 1 is selected from optionally substituted(C 1-4 )alkoxy, halo, cyano, optionally substituted(C 1-6 )alkyl or optionally substituted pheny
  • R 1 is optionally substituted (C 1 .4 )alkoxy, halo, optionally substituted ⁇ -. 6 )alkyl or optionally substituted phenyl.
  • R 1 is trifluoromethoxy, trifluoromefhyl, methoxy, (C-)alkyl, chloro, or optionally substituted phenyl.
  • Optional substituents for the groups Ar 1 , Ar 2 , R and R 1 include halogen, hydroxy, oxo, cyano, nitro, (C 1- )alkyl, (C 1-4 )alkoxy, hydroxy(C 1- )alkyl, hydroxy(C 1-4 )alkoxy, halo(C 1- )alkyl, halo(C 1-4 )alkoxy, aryl(C 1- )alkoxy, (C 1-4 )alkylthio, hydroxy(C 1- )alkyl, (C-.
  • Additional substituents are (C 1-4 )acyl, aryl, aryl(C 1-4 )alkyl, (C 1-4 )alkylamino(C 1-4 )alkyl, R ⁇ CH ⁇ n-, R a R b N(CH 2 )nO-, wherein n represents an integer from 1 to 4.
  • R a with at least one CH 2 of the (CH 2 )n portion of the group form a (C 3-6 )azacycloalkane and R represents hydrogen, a (C 1-4 )alkyl group or with the nitrogen to which it is attached forms a second (C 3-6 )azacycloalkane fused to the first (C 3-6 )azacycloalkane.
  • Preferred optional substituents for Ar 2 are halogen, cyano, (C 1- )alkyl and (C-. 4 )alkoxy.
  • Preferred optional substituents for Ar 1 are halogen and cyano.
  • R 1 Preferred optional substituents for R 1 are halogen, (C 1-4 )alkoxy and In the groups Ar 1 and Ar 2 , substituents positioned ortho to one another may be linked to form a ring.
  • Illustrative compounds of formula (I) are selected from compounds having a core structure (la)
  • halogen atom when present in the compound of fonnula (I) it may be fluorine, chlorine, bromine or iodine.
  • the alkyl group may be straight chain, branched or cyclic, or combinations thereof, it is preferably methyl or ethyl.
  • aryl means a 5- to 6- membered aromatic ring for example phenyl, or a 7 to 12 membered bicyclic ring system where at least one of the rings is aromatic for example naphthyl.
  • compounds of formula (I) may exist as R or S enantiomers.
  • the present invention includes within its scope all such isomers, including mixtures. Where additional chiral centres are present in compounds of formula (I), the present invention includes within its scope all possible diastereoismers, including mixtures thereof.
  • the different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer maybe obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.
  • Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically acceptable derivatives.
  • pharmaceutically acceptable derivative includes any pharmaceutically acceptable salt, ester or salt of such ester of a compound of formula (I) which, upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.
  • salts of the compounds of formula (I) should be pharmaceutically acceptable.
  • suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid.
  • Other salts e.g. oxalates, maybe used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention.
  • solvates and hydrates of compounds of formula (I) are also included within the scope of the invention. Certain of the compounds of formula (I) may form acid addition salts with one or more equivalents of the acid.
  • the present invention includes within its scope all possible stoichiometric and non-stoichiometric forms.
  • the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60%> pure, more suitably at least 75 %> pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions. According to a further aspect of the present invention there is provided a process for the preparation of compounds of formula (I) and derivatives thereof. The following schemes detail some synthetic routes to compounds of the invention.
  • Examples of suitable leaving groups L 1 include halogen, hydroxy, OSO 2 Me, OSO (4-tolyl).
  • the reaction of (V) with (VT) preferably proceeds in an inert solvent such as N,N-dimethylformamide in the presence of abase such as triethylamine, sodium hydride or potassium t-butoxide.
  • Sulphonamide formation eg. (IT) to (I) maybe carried out in an inert solvent such as dichloromethane, in the presence of a base such as Iriethylamine.
  • protecting groups P include t-butyloxycarbonyl, trifluoroacetyl , optionally substitued benzyl and benzyloxycarbonyl.
  • Deprotection conditions are respectively, acid (e.g. trifluoroacetic acid in dichloromethane), base (e.g. sodium hydroxide in a solvent such as aqueous methanol) and catalytic hydrogenolysis in an inert solvent (e.g using palladium on charcoal in a lower alcohol or ethyl acetate).
  • Reaction of (VIH) with (LX) proceeds in an inert solvent such as dimethylformamide or xylene in the presence of a base such as potassium carbonate or diisopropylethylamine, preferably at elevated temperatures.
  • P can be a protecting group or H.
  • Reaction of (XI) with an alkylating agent (C ⁇ L 1 proceeds in the presence of a base such as sodium hydride in an inert solvent such as dimethylformamide.
  • R 1 When R 1 is an aromatic group, the substituent R 1 may be introduced at the final stage as illustrated in Scheme 2 by reaction of a compound of formula (VII) where L 3 represents a leaving group such as halogen (preferably bromo or iodo) or tiifluoromethylsulfonyloxy, and all other variables are as previously defined, with a reagent R ! M, where M is the residue of an organometallic species e.g. B(OH) or trialkylstannyl.
  • a process may be carried out in an inert solvent such as 1,2-dimethoxyethane or 1,4- dioxan, in the presence of a transition metal catalyst such as Pd(PPh 3 ) .
  • Ar 2 , m, p, q, Ar 1 , R, R 1 and Y are as defined for compounds of formula (I).
  • L is a leaving group
  • Acylation may be carried out using a wide range of known acylation conditions, e.g. in an inert solvent such as dichloromethane, in the presence of a base such as triethylamine.
  • these steps may be carried out when L 4 represents hydroxy, in which case the reaction takes place in an inert solvent such as dichloromethane in the presence of a diimide reagent such as l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and an activator such as 1- hydroxybenzotriazole.
  • the compounds of formula (T) may be prepared singly or as compound libraries comprising at least 2, e.g. 5 to 1000, preferably 10 to 100 compounds of formula (I).
  • Compound libraries may be prepared by a combinatorial 'split and mix' approach or by multiple parallel synthesis using either solution phase or solid phase chemistry, by procedures known to those skilled in the art.
  • a compound library comprising at least 2 compounds of formula (I), or pharmaceutically acceptable derivatives thereof.
  • compositions may be prepared conventionally by reaction with the appropriate acid or acid derivative.
  • the compounds of formula (I) and their pharmaceutically acceptable derivatives are useful for the treatment of diseases or disorders where an antagonist of a human Orexin receptor is required such as obesity and diabetes; prolactinoma; hypoprolactinemia; hypothalamic disorders of growth hormone deficiency; idiopathic growth hormone deficiency; Cushings syndrome/disease; hypothalamic-adrenal dysfunction; dwarfism; sleep disorders; sleep apnea; narcolepsy; insomnia; parasornnia; jet-lag syndrome; sleep disturbances associated with diseases such as neurological disorders, neuropathic pain and restless leg syndrome; heart and lung diseases; depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis/disorder; depressive neurosis/disorder; anxiety neurosis; dysthymic disorder; behaviour disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; sex disorder; sexual disorder; schizophrenia; manic depression; delerium; dementia; bulimia and hypopit
  • the compounds of formula (I) and their pharmaceutically acceptable derivatives are particularly useful for the treatment of obesity, including obesity associated with Type 2 diabetes, and sleep disorders. Additionally the compounds of formula (I) and pharmaceutically acceptable derivatives are useful for the treatment of stroke, particularly ischemic or haemorrhagic and/or in blocking an emetic response i.e. nausea and vomiting.
  • diseases or disorders which maybe treated in accordance with the invention include disturbed biological and circadian rhythms; adrenohypophysis disease; hypophysis disease; hypophysis tumor / adenoma; adrenohypophysis hypofunction; functional or psychogenic amenorrhea; adrenohypophysis hyperfunction; migraine; hyperalgesia; pain; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndromes I and II; arthritic pain; sports injury pain; pain related to infection e.g.
  • the invention also provides a method of treating or preventing diseases or disorders where an antagonist of a human Orexin receptor is required, which comprises admiriistering to a subject in need thereof an effective amount of a compound of formula (I), or a pharmaceutically acceptable derivative thereof.
  • the invention also provides a compound of formula (I), or a pharmaceutically acceptable derivative thereof, for use in the treatment or prophylaxis of diseases or disorders where an antagonist of a human Orexin receptor is required.
  • the invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment or prophylaxis of diseases or disorders where an antagonist of a human Orexin receptor is required.
  • the compounds of the invention are usually administered as a pharmaceutical composition.
  • the invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
  • the compounds of formula (I) and their pharmaceutically acceptable derivatives may be administered by any convenient method, e.g. by oral, parenteral, buccal, sublingual, nasal, rectal or transdermal administration, and the pharmaceutical compositions adapted accordingly.
  • the compounds of formula (I) and their pharmaceutically acceptable derivatives which are active when given orally can be formulated as liquids or solids, e.g. as syrups, suspensions, emulsions, tablets, capsules or lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the active ingredient in a suitable liquid carrier(s) e.g. an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil.
  • a suitable liquid carrier(s) e.g. an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil.
  • the formulation may also contain a suspending agent, preservative, flavouring and/or colouring agent.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations, such as magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures, e.g. pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), e.g. aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • suitable pharmaceutical carrier(s) e.g. aqueous gums, celluloses, silicates or oils
  • compositions consist of a solution or suspension of the active ingredient in a sterile aqueous carrier or parenterally acceptable oil, e.g. polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • a sterile aqueous carrier or parenterally acceptable oil e.g. polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
  • Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders.
  • Aerosol formulations typically comprise a solution or fine suspension of the active ingredient in a pharmaceutically acceptable aqueous or non- aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container which can take the form of a cartridge or refill for use with an atomising device.
  • the sealed container may be a disposable dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve.
  • the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas e.g. air, or an organic propellant such as a fluorochlorohydrocarbon or hydrofluorocarbon.
  • Aerosol dosage forms can also take the form of pump-atomisers.
  • Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles where the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
  • compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.
  • compositions suitable for transdermal administration include ointments, gels and patches.
  • the composition is in unit dose form such as a tablet, capsule or ampoule.
  • the dose of the compound of formula (I), or a pharmaceutically acceptable derivative thereof, used in the treatment or prophylaxis of the abovementioned disorders or diseases will vary in the usual way with the particular disorder or disease being treated, the weight of the subject and other similar factors.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 500 mg.
  • Unit doses may be administered more than once a day for example two or three times a day, so that the total daily dosage is in the range of about 0.01 to 100 mg kg; and such therapy may extend for a number of weeks or months, fn the case of pharmaceutically acceptable derivatives the above figures are calculated as the parent compound of formula (I).
  • Human Orexin-A has the amino acid sequence: pyroGlu Pro Leu Pro Asp Cys Cys Arg Gin Lys Thr Cys Ser Cys Arg Leu 1 5 10 15
  • Orexin-A can be employed in screening procedures for compounds which inhibit the ligand's activation of the orexin-1 receptor.
  • screening procedures involve providing appropriate cells which express the orexin-1 receptor on their surface.
  • Such cells include cells from mammals, yeast, Drosophila or E. coli.
  • a polynucleotide encoding the orexin-1 receptor is used to transfect cells to express the receptor.
  • the expressed receptor is then contacted with a test compound and an orexin-1 receptor ligand to observe inhibition of a functional '- ⁇ response.
  • One such screening procedure involves the use of melanophores which are transfecte'Mo express the orexin-1 receptor, as described in WO 92/01810.
  • Another screening procedure involves introducing RNA encoding the orexin-1 receptor into Xenopus oocytes to transiently express the receptor.
  • the receptor oocytes are then contacted with a receptor ligand and a test compound, followed by detection of inhibition of a signal in the case of screening for compounds which are thought to inhibit activation of the receptor by the ligand.
  • Another method involves screening for compounds which inhibit activation of the receptor by deterrmning inhibition of binding of a labelled orexin-1 receptor ligand to cells which have the receptor on their surface.
  • This method involves transfecting a eukaryotic cell with DNA encoding the orexin-1 receptor such that the cell expresses the receptor on its surface and contacting the cell or cell membrane preparation with a compound in the presence of a labelled form of an orexin-1 receptor ligand.
  • the ligand may contain a radioactive label. The amount of labelled ligand bound to the receptors is measured, e.g. by measuring radioactivity.
  • Yet another screening technique involves the use of FLIPR equipment for high throughput screening of test compounds that inhibit mobilisation of intracellular calcium ions, or other ions, by affecting the interaction of an orexin-1 receptor ligand with the orexin-1 receptor.
  • Example 1 Benzofuran-4-carboxylic acid ((S)-l-(naphthalene-l-sulfonyl)-piperidin-2- ylmethyl)amide
  • the compounds of examples 3 to 23 have the core structure (la)
  • the orexin-1 receptor antagonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.
  • CHO-DG44 cells expressing the human orexin-1 receptor were grown in cell medium (MEM medium with Earl's salts) containing 2 mM L-Glutamine, 0.4 mg/mL G418 Sulphate from GD3CO BRL and 10% heat inactivated fetal calf serum from Gibco BRL.
  • the cells were seeded at 20,000 cells/100 ⁇ l/well into 96-well black clear bottom sterile plates from Costar which had been pre-coated with 10 ⁇ g/well of poly-L-lysine from SIGMA. The seeded plates were incubated overnight at 37C in 5% CO 2 .
  • Agonists were prepared as 1 mM stocks in water:DMSO (1:1). EC50 values (the concentration required to produce 50% maximal response) were estimated using 1 lx half log unit dilutions (Biomek 2000, Beckman) in Tyrode's buffer containing probenecid (10 mM HEPES with 145mM NaCl, lOmM glucose, 2.5 mM KC1, 1.5 mM CaCl 2 , 1.2 mM MgCl 2 and 2.5mM probenecid; pH7.4). Antagonists were prepared as 10 mM stocks in DMSO (100%).
  • Antagonist IC50 values (the concentration of compound needed to inhibit 50% of the agonist response) were determined against 3.0 nM human orexin-A using 1 lx half log unit dilutions in Tyrode's buffer containing 10%o DMSO and probenecid.
  • Kb IC50/(l+([3/EC50]) where EC50 was the potency of human orexin-A determined in the assay (in nM terms) and IC50 is expressed in molar terms.
  • Compounds of Examples tested according to this method had pKb values in the range 6.9 to 8.6 at the human cloned orexin-1 receptor.
  • the orexin-2 receptor antagonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.
  • CHO-DG44 cells expressing the human orexin-2 receptor were grown in cell medium (MEM medium with Earl's salts) contaimng 2 mM L-Glutamine, 0.4 mg/mL G418 Sulphate from GIBCO BRL and 10%) heat inactivated fetal calf serum from Gibco BRL.
  • the cells were seeded at 20,000 cells/100 ⁇ l/well into 96-well black clear bottom sterile plates from Costar which had been pre-coated with 10 ⁇ g/well of poly-L-lysine from SIGMA. The seeded plates were incubated overnight at 37C in 5% CO 2 .
  • Agonists were prepared as 1 mM stocks in wate ⁇ DMSO (1:1).
  • EC50 values (the concentration required to produce 50% maximal response) were estimated using 1 lx half log unit dilutions (Biomek 2000, Beckman) in Tyrode's buffer containing probenecid (10 mM HEPES with 145mM NaCl, lOmM glucose, 2.5 mM KC1, 1.5 mM CaCl 2 , 1.2 mM MgCl 2 and 2.5mM probenecid; pH7.4). Antagonists were prepared as 10 mM stocks in DMSO (100%).
  • Antagonist IC50 values (the concentration of compound needed to inhibit 50% of the agonist response) were determined against 10.0 nM human orexin-A using 1 lx half log unit dilutions in Tyrode's buffer containing 10% DMSO and probenecid.
  • Antagonist or buffer (25 ⁇ l) was added (Quadra) the cell plates gently shaken and incubated at 37C in 5%> CO for 30 min. Cell plates were then transferred to the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices) instrument. Prior to drug addition a single image of the cell plate was taken (signal test), to evaluate dye loading consistency. The run protocol used 60 images taken at 1 second intervals followed by a further 24 images at 5 second intervals. Agonists were added (by the FLIPR) after 20 sec (during continuous reading). From each well, peak fluorescence was determined over the whole assay period and the mean of readings 1-19 inclusive was subtracted from this figure.
  • FLIPR Fluorescent Imaging Plate Reader
  • Kb IC50/(l+([3/EC50]) where EC50 was the potency of human orexin-A determined in the assay (in nM terms) and IC50 is expressed in molar tenns.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des dérivés d'amine cyclique N-aryle sulphonyle et leur utilisation comme produits pharmaceutiques.
PCT/EP2003/012406 2002-11-06 2003-11-04 Nouveaux composes WO2004041807A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003279366A AU2003279366A1 (en) 2002-11-06 2003-11-04 Novel compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0225938.0 2002-11-06
GBGB0225938.0A GB0225938D0 (en) 2002-11-06 2002-11-06 Novel compounds

Publications (1)

Publication Number Publication Date
WO2004041807A1 true WO2004041807A1 (fr) 2004-05-21

Family

ID=9947352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/012406 WO2004041807A1 (fr) 2002-11-06 2003-11-04 Nouveaux composes

Country Status (3)

Country Link
AU (1) AU2003279366A1 (fr)
GB (1) GB0225938D0 (fr)
WO (1) WO2004041807A1 (fr)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007085718A1 (fr) * 2006-01-27 2007-08-02 Sanofi-Aventis Derives de sulfonamides, leur preparation et leur application en tant qu'antagonistes des recepteurs de l'orexine 2
WO2008008517A2 (fr) 2006-07-14 2008-01-17 Merck & Co., Inc. Diazépans pontés antagonistes du récepteur de l'oréxine
WO2008038251A2 (fr) * 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd Dérivés du 3-aza-bicyclo[3.1.0]hexane
US7365077B2 (en) 2001-11-10 2008-04-29 Smithkline Beecham P.L.C. Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor
WO2008069997A1 (fr) 2006-12-01 2008-06-12 Merck & Co., Inc. Antagonistes des récepteurs de l'orexine sous forme de composés de diazépane substitués
WO2008147518A1 (fr) 2007-05-23 2008-12-04 Merck & Co., Inc. Antagonistes de récepteur d'orexine pipéridyl pipéridine
WO2008150364A1 (fr) 2007-05-23 2008-12-11 Merck & Co., Inc. Antagonistes du récepteur de la cyclopropylpyrrolidine orexine
US7763638B2 (en) 2004-03-01 2010-07-27 Actelion Pharmaceuticals Ltd. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
WO2012025877A1 (fr) 2010-08-24 2012-03-01 Actelion Pharmaceuticals Ltd Dérivés de proline sulfonamide comme antagonistes des récepteurs de l'orexine
US8133901B2 (en) 2006-12-01 2012-03-13 Actelion Pharmaceuticals Ltd. 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors
US8236964B2 (en) 2007-03-26 2012-08-07 Actelion Pharmaceuticals Ltd. Thiazolidine derivatives as orexin receptor antagonists
US8236801B2 (en) 2008-02-21 2012-08-07 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
US8288411B2 (en) 2007-09-24 2012-10-16 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
US8288435B2 (en) 2006-12-28 2012-10-16 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
US8288429B2 (en) 2007-07-27 2012-10-16 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[3.3.0]octane derivatives
WO2013182972A1 (fr) 2012-06-04 2013-12-12 Actelion Pharmaceuticals Ltd Dérivés de benzimidazole-proline
WO2014057435A1 (fr) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Antagonistes des récepteurs de l'orexine, qui sont des dérivés [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone
WO2014141065A1 (fr) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Dérivés d'amide d'azétidine en tant qu'antagonistes des récepteurs d'oréxine
WO2015083094A1 (fr) 2013-12-04 2015-06-11 Actelion Pharmaceuticals Ltd Utilisation de dérivés de benzimidazole-proline
WO2015083070A1 (fr) 2013-12-03 2015-06-11 Actelion Pharmaceuticals Ltd Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
WO2015083071A1 (fr) 2013-12-03 2015-06-11 Actelion Pharmaceuticals Ltd Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine
US9156819B2 (en) 2011-10-19 2015-10-13 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US9499517B2 (en) 2012-02-07 2016-11-22 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
WO2017194548A1 (fr) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de maladies inflammatoires auto-immunes
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
WO2020007964A1 (fr) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd Dérivés de 2-(2-azabicyclo [3.1.0] hexan-1-yl)-1h-benzimidazole
WO2020099511A1 (fr) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Dérivés de benzimidazole-2-méthyl-morpholine
US10894789B2 (en) 2016-02-12 2021-01-19 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
WO2023218023A1 (fr) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Dérives d'hydrazine-n-carboxamide cycliques substitués par thiazoloaryl-méthyle

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048681A1 (fr) * 1996-06-20 1997-12-24 Smithkline Beecham Plc Derives du sulfonamide et leur utilisation dans le traitement des troubles du systeme nerveux central
EP0999205A1 (fr) * 1997-07-24 2000-05-10 Mitsubishi-Tokyo Pharmaceuticals, Inc. Composes d'aminocycloalcane
WO2001022966A1 (fr) * 1999-09-30 2001-04-05 Smithkline Beecham Corporation Caspases et apoptose
WO2001096302A1 (fr) * 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Piperidines utiles en tant qu'antagonistes du recepteur d'orexine
WO2002002554A1 (fr) * 2000-06-30 2002-01-10 F. Hoffmann-La Roche Ag Derives de sulfonyl-pyrrolidine utilises dans le traitement des troubles neurologiques
WO2002044172A1 (fr) * 2000-11-28 2002-06-06 Smithkline Beecham P.L.C. Derives de la morpholine utilises comme antagonistes des recepteurs de l'orexine
WO2002090355A1 (fr) * 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. Amines cycliques n-aroyle
WO2003028641A2 (fr) * 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Antagonistes du recepteur de la mch
WO2003041711A1 (fr) * 2001-11-10 2003-05-22 Smithkline Beecham P.L.C. Derives bis-amide de piperazine et leur utilisation en tant qu'antagonistes du recepteur d'orexine

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048681A1 (fr) * 1996-06-20 1997-12-24 Smithkline Beecham Plc Derives du sulfonamide et leur utilisation dans le traitement des troubles du systeme nerveux central
EP0999205A1 (fr) * 1997-07-24 2000-05-10 Mitsubishi-Tokyo Pharmaceuticals, Inc. Composes d'aminocycloalcane
WO2001022966A1 (fr) * 1999-09-30 2001-04-05 Smithkline Beecham Corporation Caspases et apoptose
WO2001096302A1 (fr) * 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Piperidines utiles en tant qu'antagonistes du recepteur d'orexine
WO2002002554A1 (fr) * 2000-06-30 2002-01-10 F. Hoffmann-La Roche Ag Derives de sulfonyl-pyrrolidine utilises dans le traitement des troubles neurologiques
WO2002044172A1 (fr) * 2000-11-28 2002-06-06 Smithkline Beecham P.L.C. Derives de la morpholine utilises comme antagonistes des recepteurs de l'orexine
WO2002090355A1 (fr) * 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. Amines cycliques n-aroyle
WO2003028641A2 (fr) * 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Antagonistes du recepteur de la mch
WO2003041711A1 (fr) * 2001-11-10 2003-05-22 Smithkline Beecham P.L.C. Derives bis-amide de piperazine et leur utilisation en tant qu'antagonistes du recepteur d'orexine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS XP002268379, retrieved from STN accession no. 2003:282325 Database accession no. 138:321285 *
DOKUZOVIC, Z.; ET AL: "Asymmetric Synthesis. Metal Complex Mediated Synthesis of Chiral Glycine by Enantioselective Proton Exchange", J.AM.CHEM.SOC., vol. 108, no. 8, 1986, pages 2034 - 2039, XP002268378 *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365077B2 (en) 2001-11-10 2008-04-29 Smithkline Beecham P.L.C. Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor
US7763638B2 (en) 2004-03-01 2010-07-27 Actelion Pharmaceuticals Ltd. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
WO2007085718A1 (fr) * 2006-01-27 2007-08-02 Sanofi-Aventis Derives de sulfonamides, leur preparation et leur application en tant qu'antagonistes des recepteurs de l'orexine 2
FR2896798A1 (fr) * 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
US7968534B2 (en) 2006-01-27 2011-06-28 Sanofi-Aventis Sulfonamide derivatives, preparation thereof and use thereof as antagonists of orexin 2 receptors
WO2008008517A2 (fr) 2006-07-14 2008-01-17 Merck & Co., Inc. Diazépans pontés antagonistes du récepteur de l'oréxine
JP2009543785A (ja) * 2006-07-14 2009-12-10 メルク エンド カムパニー インコーポレーテッド 架橋ジアゼパンオレキシン受容体アンタゴニスト
WO2008038251A2 (fr) * 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd Dérivés du 3-aza-bicyclo[3.1.0]hexane
WO2008038251A3 (fr) * 2006-09-29 2008-06-26 Actelion Pharmaceuticals Ltd Dérivés du 3-aza-bicyclo[3.1.0]hexane
JP2010504957A (ja) * 2006-09-29 2010-02-18 アクテリオン ファーマシューティカルズ リミテッド ３−アザ−ビシクロ［３．１．０］ヘキサン誘導体
WO2008069997A1 (fr) 2006-12-01 2008-06-12 Merck & Co., Inc. Antagonistes des récepteurs de l'orexine sous forme de composés de diazépane substitués
US8133901B2 (en) 2006-12-01 2012-03-13 Actelion Pharmaceuticals Ltd. 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors
EP2392572A1 (fr) 2006-12-01 2011-12-07 Merck Sharp & Dohme Corp. Antagonistes des récepteurs de l'orexine sous forme de composés de diazépane substitués
US8288435B2 (en) 2006-12-28 2012-10-16 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
US8236964B2 (en) 2007-03-26 2012-08-07 Actelion Pharmaceuticals Ltd. Thiazolidine derivatives as orexin receptor antagonists
WO2008150364A1 (fr) 2007-05-23 2008-12-11 Merck & Co., Inc. Antagonistes du récepteur de la cyclopropylpyrrolidine orexine
US8242121B2 (en) 2007-05-23 2012-08-14 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
US8569311B2 (en) 2007-05-23 2013-10-29 Merch Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
WO2008147518A1 (fr) 2007-05-23 2008-12-04 Merck & Co., Inc. Antagonistes de récepteur d'orexine pipéridyl pipéridine
US8288429B2 (en) 2007-07-27 2012-10-16 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[3.3.0]octane derivatives
US8288411B2 (en) 2007-09-24 2012-10-16 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
US8236801B2 (en) 2008-02-21 2012-08-07 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
US9000029B2 (en) 2010-08-24 2015-04-07 Actelion Pharmaceuticals Ltd. Proline sulfonamide derivatives as orexin receptor antagonists
WO2012025877A1 (fr) 2010-08-24 2012-03-01 Actelion Pharmaceuticals Ltd Dérivés de proline sulfonamide comme antagonistes des récepteurs de l'orexine
JP2013538206A (ja) * 2010-08-24 2013-10-10 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体
US9211279B2 (en) 2010-08-24 2015-12-15 Actelion Pharmaceuticals Ltd. Proline sulfonamide derivatives as orexin receptor antagonists
US8895606B2 (en) 2010-08-24 2014-11-25 Actelion Pharmaceuticals Ltd. Proline sulfonamide derivatives as orexin receptor antagonists
US9156819B2 (en) 2011-10-19 2015-10-13 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US9896452B2 (en) 2012-02-07 2018-02-20 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US9499517B2 (en) 2012-02-07 2016-11-22 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US10329287B2 (en) 2012-06-04 2019-06-25 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
US9732075B2 (en) 2012-06-04 2017-08-15 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
US11040966B2 (en) 2012-06-04 2021-06-22 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
WO2013182972A1 (fr) 2012-06-04 2013-12-12 Actelion Pharmaceuticals Ltd Dérivés de benzimidazole-proline
WO2014057435A1 (fr) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Antagonistes des récepteurs de l'orexine, qui sont des dérivés [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone
US9493446B2 (en) 2012-10-10 2016-11-15 Actelion Pharmaceuticals Ltd. Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
US9403813B2 (en) 2013-03-12 2016-08-02 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
WO2014141065A1 (fr) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Dérivés d'amide d'azétidine en tant qu'antagonistes des récepteurs d'oréxine
US9914720B2 (en) 2013-12-03 2018-03-13 Idorsia Pharmaceuticals Ltd Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
US9790208B2 (en) 2013-12-03 2017-10-17 Idorsia Pharmaceuticals Ltd Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
WO2015083070A1 (fr) 2013-12-03 2015-06-11 Actelion Pharmaceuticals Ltd Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
US10023560B2 (en) 2013-12-03 2018-07-17 Idorsia Pharmaceuticals Ltd Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
WO2015083071A1 (fr) 2013-12-03 2015-06-11 Actelion Pharmaceuticals Ltd Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine
US9914721B2 (en) 2013-12-04 2018-03-13 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
WO2015083094A1 (fr) 2013-12-04 2015-06-11 Actelion Pharmaceuticals Ltd Utilisation de dérivés de benzimidazole-proline
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
US10894789B2 (en) 2016-02-12 2021-01-19 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
US11434236B2 (en) 2016-02-12 2022-09-06 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
WO2017194548A1 (fr) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de maladies inflammatoires auto-immunes
WO2020007964A1 (fr) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd Dérivés de 2-(2-azabicyclo [3.1.0] hexan-1-yl)-1h-benzimidazole
WO2020099511A1 (fr) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Dérivés de benzimidazole-2-méthyl-morpholine
WO2023218023A1 (fr) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Dérives d'hydrazine-n-carboxamide cycliques substitués par thiazoloaryl-méthyle

Also Published As

Publication number Publication date
GB0225938D0 (en) 2002-12-11
AU2003279366A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
EP1539747B1 (fr) Amines cycliques n-aroyle utilisees comme antagonistes du recepteur d'orexine
EP1353918B1 (fr) Derives de la morpholine utilises comme antagonistes des recepteurs de l'orexine
US6677354B2 (en) Piperdines for use as orexin receptor antagonists
WO2004041807A1 (fr) Nouveaux composes
EP1456203B1 (fr) Derives d'ethylene diamine et utilisation en tant qu'antagonistes de recepteurs d'orexine
WO2004041791A1 (fr) Derives d'amine cyclique n-aryle acetyle utilises comme antagonistes de l'orexine
US7405217B2 (en) N-aroyl piperazine derivatives as orexin receptor antagonists
US7365077B2 (en) Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor
WO2003051873A1 (fr) Composes de piperazine et leur utilisation pharmaceutique
EP1385845B1 (fr) Amines cycliques n-aroyle
US20040192673A1 (en) N-aroyl cyclic amine derivatives as orexin receptor antagonists
WO2004041816A1 (fr) Compositions azacycliques utilisees comme antagonistes du recepteur de l'orexine
WO2003051368A1 (fr) Derives d'amine cyclique n-aroyle utilises en tant qu'antagonistes du recepteur d'orexine
EP1075478A1 (fr) Derives de phenyluree et de (phenylthio)uree
WO2003051871A1 (fr) Derives d'amine cyclique n-aroyle et leur utilisation en tant qu'antagonistes recepteurs d'orexine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP